AbCellera Biologics Inc (ABCL) - Long-Term Debt to Capital Coefficient

This daily price chart for AbCellera Biologics (ABCL) on the GURU.Markets platform reflects the dynamics of a company establishing its own Canadian antibody production capacities to ensure independence. Its leadership in immunology and AI technology attracts the market's largest players. The current metric stands at 0.14, while the business relies on stable royalty payments, and long-term development cycles are already priced in.

This indicator determines the ratio of long-term liabilities to equity, measuring the degree of financial leverage and the resilience of the balance sheet structure to external shocks. By analyzing the long-term debt load on capital, an investor assesses the ability of AbCellera Biologics (ABCL) to fund the development of its AI platform and maintain FDA compliance without critical dependence on borrowed funds, which minimizes bankruptcy risk during prolonged consolidation.